Paingone Freeze 5
Menthol
Quality Health Innovations Limited
Human Otc Drug
NDC 80223-002Paingone Freeze 5 also known as Menthol is a human otc drug labeled by 'Quality Health Innovations Limited'. National Drug Code (NDC) number for Paingone Freeze 5 is 80223-002. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Paingone Freeze 5 drug includes Menthol - 5 g/100mL . The currest status of Paingone Freeze 5 drug is Active.
Drug Information:
| Drug NDC: | 80223-002 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Paingone Freeze 5 |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Menthol |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Quality Health Innovations Limited |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Gel |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | MENTHOL - 5 g/100mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Jun, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 14 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part348 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | QUALITY HEALTH INNOVATIONS LIMITED
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 415975
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | L7T10EIP3A
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 80223-002-01 | 177 mL in 1 TUBE (80223-002-01) | 01 Jun, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose cooling pain relief
Product Elements:
Paingone freeze 5 menthol water aloe vera leaf alcohol arnica montana flower propylene glycol carbomer interpolymer type a (allyl sucrose crosslinked) pyridoxine hydrochloride dimethyl sulfone aminomethylpropanol fd&c blue no. 1 menthol menthol
Indications and Usage:
Uses temporary pain relief associated with sprains, strains, backache, arthritis, aching muscles and joints.
Warnings:
Warnings for external use only. flammable : keep away from open flame or excessive heat. ask a doctor before use if you are: pregnant or breastfeeding, suffering from a skin condition. when using this product : avoid contact with the eyes or mucous membranes. do not apply to wounds or inflamed or broken skin. cease use if a rash or irritation occurs. do not use with other topical treatments. do not use under bandages or occlusive dressings stop use and ask a doctor if : condition worsens, symptoms persist for more than 7 days, symptoms clear up and recur within a few days keep out of reach of children : if swallowed, get medical help or contact a poison control center immediately
Dosage and Administration:
Directions adults and children 2 years and older : apply a small amount to the affected area and massage gently, no more than 4 times per day. wash hands with cool water after use. children under 2 years of age : consult a doctor.
Package Label Principal Display Panel:
Product label image description